marked.bio

Company

Akeso

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

cadonilimab 1ivonescimab 1

Trials

2 of 4 trials shown

  1. Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

    Recruiting Phase 3 Akeso Started 2026Primary completion 2030-06 NCT07412613

    cadonilimaboxaliplatincapecitabinefluorouracilleucovorin

    Microsatellite instability detection demostrates MSI-H (with 5 NCI-recommended microsatellite detection sites: BAT25, BAT26, D5S346, D2S123, D17…

    MSI-H / dMMRResectable Colon Cancer, MSI-H/dMMR Colorectal Cancer

  2. Phase 3 Clinical Study of AK112 for NSCLC Patients

    Active, not recruiting Phase 3 Akeso Started 2022Primary completion 2023-03 NCT05184712

    ivonescimabpemetrexedcarboplatin

    The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment

    EGFR exon 19 deletion / L858RNon-Squamous Non-small Cell Lung Cancer